These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 37551891

  • 1. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.
    Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, Hu X, Shi Y.
    Thorac Cancer; 2023 Sep; 14(25):2536-2547. PubMed ID: 37551891
    [Abstract] [Full Text] [Related]

  • 2. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis.
    Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, Petrelli F.
    Crit Rev Oncol Hematol; 2021 Sep; 165():103434. PubMed ID: 34343657
    [Abstract] [Full Text] [Related]

  • 3. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K.
    Jpn J Clin Oncol; 2019 Aug 01; 49(8):762-765. PubMed ID: 31090906
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ.
    Cancer; 2022 Feb 15; 128(4):778-787. PubMed ID: 34705268
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    Qin H, Yan H, Chen Y, Xu Q, Huang Z, Jiang W, Wang Z, Deng L, Zhang X, Zhang L, Yang N, Zeng L, Zhang Y.
    BMC Cancer; 2024 Aug 03; 24(1):952. PubMed ID: 39097705
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Cai Z, Zhan P, Song Y, Liu H, Lv T.
    Transl Lung Cancer Res; 2022 Aug 03; 11(8):1555-1566. PubMed ID: 36090645
    [Abstract] [Full Text] [Related]

  • 7. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK, Wei JL, Xu YH, Li J, Rao XR, Xu YZ, Xing BY, Zhang SJ, Chen LC, Dong XR, Zhang S, Li ZY, Liu CW, Meng R, Wu G.
    Curr Med Sci; 2023 Apr 03; 43(2):344-359. PubMed ID: 37002471
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
    Yan X, Zhao L, Wu F, Shen B, Zhou G, Feng J, Yue C, Zhu J, Yu S.
    J Thorac Dis; 2024 Mar 29; 16(3):1787-1803. PubMed ID: 38617775
    [Abstract] [Full Text] [Related]

  • 9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul 29; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 10. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M, Ji H, Xu N, Jiang P, Qu T, Li Y.
    BMC Cancer; 2022 Jul 13; 22(1):762. PubMed ID: 35831785
    [Abstract] [Full Text] [Related]

  • 11. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
    Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR.
    Clin Genitourin Cancer; 2022 Dec 13; 20(6):558-567. PubMed ID: 36155169
    [Abstract] [Full Text] [Related]

  • 12. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q, Shang X, Liu N, Ma X, Han W, Wang X, Liu Y.
    Front Immunol; 2022 Dec 13; 13():931718. PubMed ID: 35990690
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    Zhang J, Han W, Guo J, Zhang C, Cao L, Peng L, Han X, Wang Z.
    J Cancer Res Clin Oncol; 2024 Jan 27; 150(2):42. PubMed ID: 38280966
    [Abstract] [Full Text] [Related]

  • 14. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
    Bilger G, Girard N, Doubre H, Levra MG, Giroux-Leprieur E, Giraud F, Decroisette C, Carton M, Massiani MA.
    Cancer Immunol Immunother; 2022 Jul 27; 71(7):1719-1731. PubMed ID: 34821950
    [Abstract] [Full Text] [Related]

  • 15. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM.
    Eur J Cancer; 2019 Jun 27; 114():67-75. PubMed ID: 31075726
    [Abstract] [Full Text] [Related]

  • 16. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
    Tian T, Yu M, Li J, Jiang M, Ma D, Tang S, Lin Z, Chen L, Gong Y, Zhu J, Zhou Q, Huang M, Lu Y.
    Front Oncol; 2021 Jun 27; 11():739090. PubMed ID: 34888234
    [Abstract] [Full Text] [Related]

  • 17. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
    Jin Z, Cao Y, Lu Z, Liu C, Shen L.
    Int Immunopharmacol; 2024 Aug 20; 137():112364. PubMed ID: 38865752
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study.
    Yang B, Li Y, Deng J, Yang H, Sun X.
    Front Oncol; 2023 Aug 20; 13():1210267. PubMed ID: 38023216
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.
    Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T, Nishiki K, Nakase K, Nojiri M, Kato R, Shinomiya S, Fujimoto Y, Oikawa T, Mizuno S.
    Thorac Cancer; 2022 Feb 20; 13(4):624-630. PubMed ID: 34989146
    [Abstract] [Full Text] [Related]

  • 20. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
    Zu K, Arunachalam A, Hohlbauch A, Silver M, Robert N.
    Immunotherapy; 2023 Nov 20; 15(16):1375-1387. PubMed ID: 37694560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.